Clinical Research Directory

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Sponsor: Janssen Research & Development, LLC

Summary

The purpose of this pre-approval access program is to give talquetamab monotherapy (treatment with single drug) to participants with relapsed or refractory multiple myeloma (a type of cancer that begins in plasma cells \[white blood cells that produce antibodies\] which has returned or difficult to treat) who have relapsed on or are refractory to all locally available and clinically appropriate treatment and who are not eligible for a clinical trial.

Official title: 64407564MMY4003: 64407564MMY4003 - Talquetamab NPP Global

Key Details

Conditions

Interventions